PERSKY MARLA
SEC Form 4 insider trading activity
PERSKY MARLA has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Jun 5, 2026.
On the most recent filing, PERSKY MARLA is listed as Director at Xeris Biopharma Holdings, Inc. Inside the rolling window, PERSKY MARLA reported no open-market purchases and 1 open-market sale totaling $91K in XERS.
Companies traded
Other insiders at XERS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$91K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 11, 2025 | XERS | Sale | $120K |
Frequently asked questions
How many SEC Form 4 filings has PERSKY MARLA made?
PERSKY MARLA has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does PERSKY MARLA trade?
PERSKY MARLA has filed SEC Form 4 disclosures for 1 company, including XERS.
When was PERSKY MARLA's most recent SEC Form 4 filing?
PERSKY MARLA's most recent SEC Form 4 filing on Tracefour is dated Jun 5, 2026.
What is PERSKY MARLA's total buy and sell value in the current window?
Inside the rolling retention window, PERSKY MARLA bought $0 and sold $91K based on SEC Form 4 filings.
What was PERSKY MARLA's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 15,500 XERS shares on 2026-06-03, worth $91K, per SEC Form 4 filings.